Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30173
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRouxel, Flavien-
dc.contributor.authorRelator, Raissa-
dc.contributor.authorKerkhof, Jennifer-
dc.contributor.authorMcConkey, Haley-
dc.contributor.authorLevy, Michael-
dc.contributor.authorDias, Patricia-
dc.contributor.authorBarat-Houari, Mouna-
dc.contributor.authorBednarek, Nathalie-
dc.contributor.authorBoute, Odile-
dc.contributor.authorChatron, Nicolas-
dc.contributor.authorCherik, Florian-
dc.contributor.authorDelahaye-Duriez, Andrée-
dc.contributor.authorDoco-Fenzy, Martine-
dc.contributor.authorFaivre, Laurence-
dc.contributor.authorGauthier, Lucas W-
dc.contributor.authorHeron, Delphine-
dc.contributor.authorHildebrand, Michael S-
dc.contributor.authorLesca, Gaëtan-
dc.contributor.authorLespinasse, James-
dc.contributor.authorMazel, Benoit-
dc.contributor.authorMenke, Leonie A-
dc.contributor.authorMorgan, Angela T-
dc.contributor.authorPinson, Lucile-
dc.contributor.authorQuelin, Chloe-
dc.contributor.authorRossi, Massimiliano-
dc.contributor.authorRuiz-Pallares, Nathalie-
dc.contributor.authorTran-Mau-Them, Frederic-
dc.contributor.authorVan Kessel, Imke N-
dc.contributor.authorVincent, Marie-
dc.contributor.authorWeber, Mathys-
dc.contributor.authorWillems, Marjolaine-
dc.contributor.authorLeguyader, Gwenael-
dc.contributor.authorSadikovic, Bekim-
dc.contributor.authorGenevieve, David-
dc.date2022-01-19-
dc.date.accessioned2022-06-23T00:26:21Z-
dc.date.available2022-06-23T00:26:21Z-
dc.date.issued2022-05-
dc.identifier.citationGenetics in Medicine 2022; 24(5): 1096-1107en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30173-
dc.description.abstractRare genetic variants in CDK13 are responsible for CDK13-related disorder (CDK13-RD), with main clinical features being developmental delay or intellectual disability, facial features, behavioral problems, congenital heart defect, and seizures. In this paper, we report 18 novel individuals with CDK13-RD and provide characterization of genome-wide DNA methylation. We obtained clinical phenotype and neuropsychological data for 18 and 10 individuals, respectively, and compared this series with the literature. We also compared peripheral blood DNA methylation profiles in individuals with CDK13-RD, controls, and other neurodevelopmental disorders episignatures. Finally, we developed a support vector machine-based classifier distinguishing CDK13-RD and non-CDK13-RD samples. We reported health and developmental parameters, clinical data, and neuropsychological profile of individuals with CDK13-RD. Genome-wide differential methylation analysis revealed a global hypomethylated profile in individuals with CDK13-RD in a highly sensitive and specific model that could aid in reclassifying variants of uncertain significance. We describe the novel features such as anxiety disorder, cryptorchidism, and disrupted sleep in CDK13-RD. We define a CDK13-RD DNA methylation episignature as a diagnostic tool and a defining functional feature of the evolving clinical presentation of this disorder. We also show overlap of the CDK13 DNA methylation profile in an individual with a functionally and clinically related CCNK-related disorder.en
dc.language.isoeng
dc.subjectCDK13en
dc.subjectCHDFIDDen
dc.subjectClinicalen
dc.subjectEpigeneticen
dc.subjectSignatureen
dc.titleCDK13-related disorder: Report of a series of 18 previously unpublished individuals and description of an epigenetic signature.en
dc.typeJournal Articleen
dc.identifier.journaltitleGenetics in Medicine : Official Journal of the American College of Medical Geneticsen
dc.identifier.affiliationEpilepsy Research Centreen
dc.identifier.affiliationMurdoch Children's Research Institute, Department of Audiology and Speech Pathology, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Audiology and Speech Pathology, Melbourne School of Health Sciences, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationGenetics Department, Hospital Center of Lisbon North, ERN ITHACA, Lisbon, Portugalen
dc.identifier.affiliationGenetics Department, CHU Reims, Medical school IFR53, EA3801, Reims, Franceen
dc.identifier.affiliationGenetics Department, Guy Fontaine Medical Center, CLAD Nord de France, Jeanne de Flandre Hospital, CHRU Lille, Lille, Franceen
dc.identifier.affiliationGenetics Department, Lyon University Hospital, and Institut NeuroMyoGène, CNRS UMR 5310 - INSERM U1217, Claude Bernard Lyon 1 University, Lyon, Franceen
dc.identifier.affiliationGenetics Department, CHU Clermont-Ferrand, Clermont-Ferrand, Franceen
dc.identifier.affiliationPROTECT, INSERM, Paris Diderot University, Paris, Franceen
dc.identifier.affiliationGenetics Department, University Hospital Pitié-Salpétrière, Paris, Franceen
dc.identifier.affiliationChromosomic genetic laboratory, CH Général, Chambéry, Franceen
dc.identifier.affiliationGénétique clinique, Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, CHU Montpellier, Montpellier University, Centre de Référence Anomalies du Développement SOOR, INSERM U1183, ERN ITHACA, Montpellier, Franceen
dc.identifier.affiliationDepartment of Clinical Genetics, CLAD Ouest, CHU de Rennes, Hôpital Sud, Rennes, Franceen
dc.identifier.affiliationDépartement de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Génétique des Maladies Rares et Auto-Inflammatoires, CHU Montpellier, Université de Montpellier, Montpellier, Franceen
dc.identifier.affiliationDepartment of Pediatrics, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, ERN ITHACA, Amsterdam, Netherlandsen
dc.identifier.affiliationGenetics Department, CHU de Nantes, Nantes, Franceen
dc.identifier.affiliationCentre de Référence Anomalies du Développement et Syndromes Malformatifs, FHU TRANSLAD, CHU Dijon, Dijon, Franceen
dc.identifier.affiliationGenetics Department, CHU de Poitiers, Poitiers University Hospital, Poitiers, Franceen
dc.identifier.affiliationDepartment of Pathology and Laboratory Medicine, Western University, London, Ontario, Canadaen
dc.identifier.affiliationThe Archie & Irene Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, Ontario, Canadaen
dc.identifier.affiliationParis 13 University, Sorbonne Paris Cité, UFR SMBH Bobignyen
dc.identifier.affiliationGenetics Department, Referral Centre for Developmental Abnormalities, Lyon University Hospital Lyon, Franceen
dc.identifier.affiliationGenetics of Developmental Disorders, INSERM - Bourgogne Franche-Comté University, UMR 1231 GAD Team, Dijon, Franceen
dc.identifier.affiliationINSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Centre, GENDEV Team, Claude Bernard Lyon 1 University, Lyon, Franceen
dc.identifier.affiliationFunctional Unit 6254 Innovation in Genomic Diagnosis of Rare Diseases, CHU Dijon Bourgogne, Dijon, Franceen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35063350/en
dc.identifier.doi10.1016/j.gim.2021.12.016en
dc.type.contentTexten
dc.identifier.orcid0000-0003-2739-0515en
dc.identifier.pubmedid35063350
local.name.researcherHildebrand, Michael S
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptEpilepsy Research Centre-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Nov 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.